SCHEMBL1128741

SCHEMBL1128741

Cc1nnnn1-c1ccc(Oc2ncnc3c2cnn3[C@H]2CC[C@H](c3nc(C(C)C)no3)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.45
CYP3A4 P08684 2/20 0.37
CNR2 P34972 1/20 0.34
FLT3 P36888 2/20 0.33
KDR P35968 5/20 0.32
BRAF P15056 3/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
NPC1 O15118 3/20 0.31
RAB9A P51151 3/20 0.31
KDM4E B2RXH2 2/20 0.31
HPGD P15428 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
TP53 P04637 2/20 0.31
POLB P06746 1/20 0.31
GABRG2 P18507 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350332 1.00 GPR119 (0.45) GPR119CYP3A4CNR2FLT3KDR
SCHEMBL4355586 0.80 CYP3A4 (0.46) CYP3A4FLT3KDRBRAFNPC1
SCHEMBL4359294 0.79 GPR119 (0.43) GPR119CYP3A4CNR2
SCHEMBL4357368 0.76 CYP3A4 (0.54) GPR119CYP3A4CYP2C9
SCHEMBL4352143 0.75 GPR119 (0.47) GPR119CYP3A4CNR2HCRTR1HCRTR2
SCHEMBL1128443 0.75 GPR119 (0.47) GPR119CYP3A4CNR2HCRTR1HCRTR2
SCHEMBL4355992 0.75 GPR119 (0.47) GPR119CYP3A4CNR2HCRTR1HCRTR2
SCHEMBL4354254 0.73 CYP3A4 (0.69) GPR119CYP3A4CYP2C9
SCHEMBL1128552 0.73 GPR119 (0.52) GPR119CYP3A4CYP2C9CYP2C19
SCHEMBL1128505 0.73 GPR119 (0.52) GPR119CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US claimed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2283019-A1 GPR119 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2011-02-16 EP disclosed
WO-2009141238-A1 GPR119 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-26 WO disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286812-A1 GPR119 Receptor Agonists GPR119, GPR27, GPR139 GPR119 1/4885CYP3A4 1503/4885CNR2 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.